MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Full Archive

The full archive of mesothelioma-related journal articles. All articles belong to this category.

About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Journal of Immunoassay & Immunochemistry 2019 February 27 [Link] Mlika M, Zorgati M, BenKhelil M, Mezni FE Abstract BACKGROUND: The positive diagnosis of MPM is based on morphologic features coupled with immunohistochemical findings. Many antibodies have been published especially in order to differentiate between malignant tumors and atypical mesothelial hyperplasia. BAP-1 is a BRCA1-binding protein […]

Comments Off on About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.

Cancer Science2019 February 22 [Link] Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, Higashi T Abstract Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy […]

Comments Off on Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.

Clinicopathological Characteristics of Well-differentiated Papillary Mesothelioma of The Peritoneum: A Single-institutional Experience of 12 Cases.

In Vivo 2019 March-April [Link] Kim M, Kim HS Abstract BACKGROUND/AIM: Well-differentiated papillary mesothelioma (WDPM) is histologically characterized by papillary architecture with fibrovascular cores, lined by bland mesothelial cells. We recently experienced a case of WDPM associated with multiple peritoneal inclusion cysts, which prompted us to initiate a comprehensive review of previously diagnosed WDPM cases. […]

Comments Off on Clinicopathological Characteristics of Well-differentiated Papillary Mesothelioma of The Peritoneum: A Single-institutional Experience of 12 Cases.

Environmental asbestos exposure in childhood and risk of mesothelioma later in life: a long-term follow-up register-based cohort study.

Occupational and Environmental Medicine 2019 February 25 [Link] Dalsgaard SB, Würtz ET, Hansen J, Røe OD, Omland Ø Abstract OBJECTIVE: To examine the risk of malignant mesothelioma (MM) in former pupils who attended primary school near an asbestos cement plant. METHODS: A cohort of 12 111 former pupils, born 1940-1970, was established from individual historical records […]

Comments Off on Environmental asbestos exposure in childhood and risk of mesothelioma later in life: a long-term follow-up register-based cohort study.

The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Annals of Surgical Oncology 2019 February 24 [Link] Lewis GD, Dalwadi SM, Farach A, Brian Butler E, Teh BS Abstract BACKGROUND: Pleural mesothelioma is a rare but aggressive form of cancer. Local recurrence represents the majority of treatment failures and overall survival (OS) outcomes remain dismal. Adding locoregional treatment with radiotherapy after surgical resection has […]

Comments Off on The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

Current Treatment Options in Oncology 2019 February 21 [Link] Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D’Argento E Abstract Unresectable or relapsed malignant pleural mesothelioma (MPM) has dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, […]

Comments Off on Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Human Pathology 2019 February 19 [Link] Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G Abstract Malignant mesothelioma (MM) is an aggressive neoplasm with poor prognosis. The Dako PD-L1 22C3 and 28-8 pharmDx assays are approved by the US Food and Drug Administration (FDA) as companion and complementary diagnostics for the anti-PD-1 […]

Comments Off on Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Genome Medicine 2019 February 18 [Link] Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen […]

Comments Off on BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.

Lasers in Surgery and Medicine 2019 February 19 [Link] Cavin S, Riedel T, Rosskopfova P, Gonzalez M, Baldini G, Zellweger M, Wagnières G, Dyson PJ, Ris HB, Krueger T, Perentes JY Abstract Vascular-targeted low-dose photodynamic therapy (L-PDT) was shown to improve chemotherapy distribution in malignant pleural tumors such as malignant pleural mesothelioma (MPM). However, the […]

Comments Off on Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Journal of Clinical Oncology 2019 February 20 [Link] Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV Abstract PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that […]

Comments Off on Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.